藥明康德(603259.SH)擬認購北海康成股份 研發罕見病藥物
藥明康德(02359.HK)(603259.SH)公布,公司全資子企業藥明基金一期、General Atlantic等8名投資人與北海康成及其他相關方簽署優先股認購協議,其中藥明基金一期擬認購北海康成新發行約169.21萬股優先股股份,認購金額約為2,000.03萬美元。
同時,北海康成還將向藥明基金一期發行一項未來可認購北海康成股份的認股權證,藥明基金一期有權在最高1,000.01萬美元的價款範圍內認購北海康成優先股股份。
投資完成後,藥明康德持有北海康成股份13.11%。北海康成專注於首創罕見病藥物的研發,具備多個罕見病藥物管線。通過關聯交易,公司將進一步完善在罕見病領域的生態圈布局,間接促進罕見病領域的新藥研發,令病患早日獲益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.